As CD44 is a multifunctional molecule involved in cancer proliferation, differentiation, migration, or angiogenesis, there have been efforts to target the CD44. However, there have been few reports on targeting metabolic genes such as HAS and HYAL to develop therapeutic agents. This evidence concerns the gene CD44 and cancer.